Retail traders showed bullish sentiment following strong Q1 revenue growth and positive clinical data for its bladder cancer drug, despite a 54% jump in short interest.
David Sacks and OpenAI CEO Sam Altman defended Donald Trump's AI chip deals with Gulf states, calling them a strategic win over China despite bipartisan concerns about national security risks.
With a breakout above key resistance and cooling volatility, Nifty enters a new phase of upward momentum. Analyst believes bulls remain in control as long as 24,800 holds.
After a strong run-up in price and record-setting highs, some are wondering if gold’s bull market has already peaked—or if this is just a pause before the next leg higher.
The New York Times reports that U.S. officials are worried the deal could boost Chinese AI capacity, spread censored chatbots, and deepen Apple's exposure to Beijing's data and censorship laws.
The company said that Govorestat slowed disease progression and improved patient outcomes in CMT-SORD, a rare hereditary neuropathy. The company plans to submit an NDA in 2025 amid strong retail investor interest.
As shares of UnitedHealth Group Inc. (NYSE: UNH) witness a steep decline, company insiders are stepping up to the plate with a series of insider buys, which analysts and experts say is "a strong signal."
Nearly 23 million Shiba Inu (CRYPTO: SHIB) were kicked out of circulation Sunday, applying further deflationary pressure on the popular dog-themed meme coin.
America’s ‘national’ debt rose from less than $6 trillion in 2000 to over $37 trillion now. The U.S. trade deficit rose to $1.1 trillion over the last 12 months — 10 times more than it was 2000.
Apple hired Google's AI chief in 2018 to boost its artificial intelligence efforts, but seven years later, it still lags behind OpenAI, Microsoft, and Amazon due to internal delays, underinvestment, and strategic missteps, according to a new report.
Senator Schumer expressed concerns about Trump and DOGE's impact on USCG operations after a Mexican vessel collided with the Brooklyn Bridge, resulting in 2 deaths.
The pharma company secured FDA clearance to manufacture and distribute its COVID-19 vaccine Nuvaxovid for adults and at-risk groups, with no advisory committee hurdles.
Is it conceivable that a reaction to Moody's move late Friday is an effort to 'bear' the market to assist the very managers who missed the move to gain entry? I certainly hope that's not the case, but the thought crossed my mind.
